Trial Profile
A Pilot Study Evaluating the Safety and Feasibility of Custirsen (OGX-011) in Combination With Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Custirsen (Primary) ; Docetaxel; Mitoxantrone; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- 25 Jul 2011 Results published in Clinical Cancer Research.
- 01 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jun 2009 Planned end date changed from Jul 2008 to Dec 2009 as reported by ClinicalTrials.gov.